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Inhibition of glycogen synthase 
kinase-3 by BTA-EG4 reduces tau 
abnormalities in an organotypic 
brain slice culture model of 
Alzheimer’s disease
Cara L. Croft1,2, Ksenia Kurbatskaya1, Diane P. Hanger1 & Wendy Noble  1
Organotypic brain slice culture models provide an alternative to early stage in vivo studies as an 
integrated tissue system that can recapitulate key disease features, thereby providing an excellent 
platform for drug screening. We recently described a novel organotypic 3xTg-AD mouse brain slice 
culture model with key Alzheimer’s disease-like changes. We now highlight the potential of this model 
for testing disease-modifying agents and show that results obtained following in vivo treatment 
are replicated in brain slice cultures from 3xTg-AD mice. Moreover, we describe novel effects of the 
amyloid-binding tetra (ethylene glycol) derivative of benzothiazole aniline, BTA-EG4, on tau. BTA-EG4 
significantly reduced tau phosphorylation in the absence of any changes in the amounts of amyloid 
precursor protein, amyloid-β or synaptic proteins. The reduction in tau phosphorylation was associated 
with inactivation of the Alzheimer’s disease-relevant major tau kinase, GSK-3. These findings highlight 
the utility of 3xTg-AD brain slice cultures as a rapid and reliable in vitro method for drug screening prior 
to in vivo testing. Furthermore, we demonstrate novel tau-directed effects of BTA-EG4 that are likely 
related to the ability of this agent to inactivate GSK-3. Our findings support the further exploration of 
BTA-EG4 as a candidate therapeutic for Alzheimer’s disease.
Alzheimer’s disease (AD) is characterised pathologically by the presence, predominantly in the hippocampus, 
neocortex and interconnecting regions, of β-amyloid (Aβ)-containing extracellular plaques and intracellular 
neurofibrillary tangles comprising hyperphosphorylated and cleaved forms of tau1–3. Associated with the devel-
opment and progression of AD are synaptic and neuronal dysfunction, widespread synaptic and neuronal loss, 
upregulation of proteolytic calpains and caspases, calcium dyshomeostasis, altered protein kinase activities, 
increased oxidative damage and activation of inflammatory cascades, all of which contribute to cognitive decline 
and other clinical symptoms of AD4–6. There are currently no disease-modifying treatments for AD, despite inten-
sive testing of potential new therapies7, 8.
BTA-EG4 is an amyloid-binding drug which reduces Aβ-induced toxicity in vitro9. BTA-EG4 readily crosses 
the blood-brain-barrier and is soluble in aqueous environments10. It has previously been shown to reduce pro-
duction of Aβ-40, and increase synaptic density and function in wild-type (WT) mice in vivo11. In addition, 
treatment of early disease-stage 3xTg-AD mice with BTA-EG4 was found to increase dendritic spine density, 
drive other alterations in spine morphology reflective of recovered synaptic function, and improve cognitive 
performance12. Tau-associated synaptotoxicity is also prevalent in AD13, 14, yet the effects of BTA-EG4 on tau have 
not been explored. Furthermore, despite its reported beneficial effects, little is known about the mode of action 
of BTA-EG4.
Typically, identification of compounds to target dementia occurs in transgenic mouse models expressing genes 
that cause familial forms of this disease. Novel methods that provide more rapid screening of drug candidates to 
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identify lead compounds prior to their pre-clinical testing in vivo would be welcomed by the field15. We have 
recently shown that some prominent molecular phenotypes of neurodegeneration exhibited by 3xTg-AD mice 
are recapitulated in organotypic brain slice cultures produced from these mice at postnatal day 8–9 and sub-
sequently maintained in culture for up to 28 days in vitro (DIV)16. 3xTg-AD brain slice cultures rapidly show 
increased production of Aβ-42, an increased Aβ-42/Aβ-40 ratio, tau phosphorylation at AD-relevant epitopes, 
such as Ser202 and Ser396/404, and tau mislocalisation and altered release when compared to control WT slice 
cultures16. Importantly, these molecular phenotypes are accelerated in culture compared to in vivo. The work pre-
sented here extends these findings and highlights 3xTg-AD brain slice cultures as a sensitive ex vivo model with 
a high potential for AD drug discovery.
We found that treating 3xTg-AD slice cultures with the GSK-3 inhibitor lithium chloride (LiCl), or the 
microtubule-binding agent NAPVSIPQ, reduces tau phosphorylation at sites implicated in AD, recapitulating 
previously reported in vivo findings in aged 3xTg-AD mice17–19. We also present novel data showing tau-directed 
effects of BTA-EG4 that are associated with BTA-EG4-mediated inhibition of GSK-3. These data highlight the 
utility of organotypic brain slice culture models for accelerated drug screening and support further exploration of 
BTA-EG4 and related derivatives for the treatment of AD and other tauopathies.
Results
Treatment of organotypic brain slice cultures from 3xTg-AD mice with LiCl and NAPVSIPQ 
recapitulates in vivo effects on tau phosphorylation. We have recently reported that organotypic 
brain slice cultures from 3xTg-AD postnatal day 8–9 mice and maintained in culture for up to 28 DIV develop 
key AD-like molecular features16 which recapitulate the in vivo degenerative phenotype observed in 3xTg-AD 
mice20, 21. These include the progressive accumulation of hyperphosphorylated tau, tau mislocalisation and altered 
tau release rates, altered APP processing and Aβ-42 accumulation16. To validate the use of this ex vivo slice culture 
model for drug discovery, we first treated the cultures with compounds previously shown to reduce tau phospho-
rylation in 3xTg-AD in vivo.
The therapeutic potential of the GSK-3 inhibitor LiCl has been widely explored in various models of AD22–25. 
Notably, LiCl treatment of 3xTg-AD mice significantly reduces tau phosphorylation at several epitopes that are 
abnormally phosphorylated in AD brain, including Thr181, Ser202/Thr205 and Thr23117. To examine the effects 
of LiCl in the 3xTg-AD ex vivo model, organotypic brain slice cultures were prepared from 3xTg-AD mice and 
aged for 28 DIV prior to treatment with 20 mM LiCl for 4 h. This dose has previously been shown to significantly 
reduce tau phosphorylation at several epitopes in primary neuronal cultures26, and does not affect neuronal via-
bility (supplementary data). Changes in the total amount of tau and tau phosphorylation were assessed by immu-
noblotting (Fig. 1a). LiCl significantly reduced tau phosphorylation at the PHF-1 (Ser396/404) epitope, whilst 
also reducing the amount of total tau (Fig. 1b) compared to control (NaCl). LiCl also increased the amount of tau 
dephosphorylated at Ser202/Thr205 relative to total tau, detected using the Tau-1 antibody. There was also a nota-
ble shift in the apparent molecular weight of tau in lysates from LiCl treated slice cultures, which is characteristic 
of reduced tau phosphorylation27. Thus, treatment of 3xTg-AD slice cultures with LiCl mimics the reduction in 
tau phosphorylation observed following treatment of 3xTg-AD mice in vivo.
NAPVSIPQ (NAP) is a neuroprotective peptide which has previously been shown to reduce tau phosphoryl-
ation in vitro and in vivo18, 19, 28, 29. Treatment of 3xTg-AD mice with NAP was shown to significantly reduce tau 
phosphorylation at Thr23118, 19, a site important for tau binding to microtubules30. Slice cultures prepared from 
3xTg-AD mice and aged for 28 DIV were treated with 100 nM NAP for 24 h prior to analysis of changes in tau 
amounts and phosphorylation at Thr231 (Fig. 1c). This concentration of NAP had previously shown efficacy to 
reduce tau phosphorylation in cultured neural cells28, without affecting neuronal viability (supplementary data). 
NAP treatment of 3xTg-AD slice cultures significantly reduced tau phosphorylation at the Tg3 (Thr231) epitope, 
but did not alter the total amount of tau when compared to control cultures (Fig. 1d). These data further confirm 
that the effects of tau-directed treatments in vivo can be recapitulated in ex vivo slice cultures that model human 
disease.
Treatment of 3xTg-AD slice cultures with BTA-EG4 reduces tau phosphorylation but does not 
alter the amount of Aβ. The effects of the amyloid-binding agent BTA-EG4 were next explored in 3xTg-AD 
slice cultures. It was first important to establish an effective dose for treatment by determining any toxicity result-
ing from 48 h treatment of 28 DIV 3xTg-AD cultures with BTA-EG4. Therefore, lactate dehydrogenase (LDH) 
release into culture medium, was calculated as a proportion of total LDH following treatment of slices with 40 μM 
or 60 μM BTA-EG4. Neither concentration of BTA-EG4 significantly affected total LDH release, indicating that 
BTA-EG4 does not cause toxicity in cultured brain slices at these concentrations (Fig. 2a). This dose was also not 
toxic to primary cultured neurons (supplementary data). This dose had previously been shown to be cytoprotec-
tive in vitro against Aβ toxicity in SH-SY5Y cells in a 24 h treatment period9
Previous reports have suggested that in vivo treatment with BTA-EG4 increases sAPPα and reduces sAPPβ, 
leading to reduced Aβ40 in the brains of WT mice11. BTA-EG4 also protects against Aβ toxicity and prevents the 
interaction of amyloid fibrils with amyloid-binding proteins in vitro9, 10. It was therefore important to determine 
whether BTA-EG4 modified APP and/or Aβ in 3xTg-AD slices, since these show altered APP processing and 
accumulation of Aβ-4216. Treatment with 40 or 60 μM BTA-EG4 did not affect levels of N-terminal APP, as meas-
ured by the 22c11 antibody, in comparison to controls (Fig. 2b,c), which is in keeping with previous findings in 
WT mice11.
3xTg-AD slice cultures produce increased amounts of Aβ-42 resulting in an altered Aβ-42/40 ratio16. 
However, a limitation of this system is that Aβ does not appear to deposit or aggregate in these slice cultures 
by 28 DIV. However, since Megill et al.11 reported that BTA-EG4 reduces the amount of Aβ-40 in the brains of 
WT mice, it was important to determine the effects of BTA-EG4 on Aβ levels in 3xTg-AD cultures. Aβ-42 and 
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Aβ-40 amounts in treated and control (DMSO) 3xTg-AD slice cultures were measured by ELISA, as previously 
described16. BTA-EG4 had no effect, compared to control, on amounts of Aβ-42, Aβ-40 or the Aβ-42/Aβ-40 ratio 
in 3xTg-AD brain slice cultures (Fig. 2d).
The effects of BTA-EG4 on tau amounts and phosphorylation were next examined by immunoblotting. 
Treatment of 3xTg-AD slices for 48 h treatment with 40 or 60 μM BTA-EG4 did not affect the amount of total 
tau, tau dephosphorylated at Ser199/202/Thr205 (Tau-1), or tau phosphorylated at Ser396/404 (PHF-1), relative 
to controls (Fig. 3a,b). In contrast, the amounts of tau phosphorylated at Ser202 (CP13) in 3xTg-AD slices were 
significantly reduced following 60 μM BTA-EG4 treatment when compared to controls (Fig. 3a,b). This significant 
reduction in tau phosphorylated at the CP13 epitope was confirmed upon immunofluorescent labelling of fixed 
brain slice cultures (Fig. 4). It is also apparent from immunolabelling that tau is redistributed from cell soma into 
axons upon BTA-EG4 treatment (Fig. 4). These findings illustrate novel tau-directed effects of BTA-EG4.
BTA-EG4 does not alter synaptic proteins in 3xTg-AD brain slice cultures. Synaptic dysfunction 
is a major correlate of early cognitive symptoms and dementia in AD31–33. It has previously been demonstrated 
Figure 1. LiCl and NAPVSIPQ reduces tau phosphorylation in organotypic brain slice cultures from 3xTg-AD 
mice. Representative western blots of lysates from 28 DIV 3xTg-AD organotypic brain slice cultures treated 
with (a) 20 mM LiCl or 20 mM NaCl (control) for 4 h, or (c) 100 nM NAP or control (H2O) for 4 h. Blots were 
probed with antibodies against total tau (both non-phosphorylated and phosphorylated; DAKO), PHF-1 
(phospho-Ser396/404), Tau-1 (dephospho-Ser202/Thr205) and Tg3 (phospho-Thr231). Blots were also probed 
with an antibody against β-actin as a loading control. Bar charts show amounts of total tau relative to β-actin in 
each sample, and phospho-tau as a proportion of total tau in each sample after treatment with (b) 20 mM LiCl 
or 20 mM NaCl (control) (all data analysed by unpaired t-test) or (d) 100 nM NAP or control (H2O). n = 9–12. 
(DAKO/actin analysed by Mann Whitney U test, Tg3/DAKO analysed by unpaired t-test). Data is mean ± SEM 
and is shown as fold change from control. *p < 0.05, **p < 0.01.
www.nature.com/scientificreports/
4SCIeNtIfIC RepORts | 7: 7434  | DOI:10.1038/s41598-017-07906-1
that BTA-EG4 increases synapse density in WT and 3xTg-AD mice11, 12. We therefore sought to determine the 
effect of BTA-EG4 treatment on synaptic protein amounts in 3xTg-AD slices. Following treatment with BTA-EG4 
or vehicle, synaptosomes were isolated from 28 DIV 3xTg-AD slice cultures and immunoblotted for pre-synaptic 
synaptophysin and post-synaptic density (PSD)-95 protein. We have previously demonstrated the stringency of 
this fractionation34. BTA-EG4 did not affect the amounts of either synaptophysin or PSD-95, relative to actin, 
suggesting that BTA-EG4 does not affect either pre-synaptic or post-synaptic integrity in 3xTg-AD slices (Fig. 5a).
We previously reported an early accumulation of tau and APP in the synaptic compartment in young 3xTg-AD 
mice, with similar changes in tau observed in 14 DIV 3xTg-AD slice cultures16. We therefore examined the effect 
of BTA-EG4 treatment on levels of APP and tau in synaptosomes from 3xTg-AD slice cultures. BTA-EG4 did not 
affect the amount of tau or APP at the synapse when compared to controls (Fig. 5b). These results are in-keeping 
with other reports that indicate highly localised effects of Aβ on tau kinases and phosphorylation35. Overall, these 
results indicate that BTA-EG4 causes reductions in tau phosphorylation at specific sites of relevance to AD in aged 
3xTg-AD brain slice cultures, and that these changes in phosphorylation do not appear to be related to changes 
in Aβ production or tau localisation.
Figure 2. BTA-EG4 treatment of 3xTg-AD brain slice cultures does not alter APP processing, amyloid load 
or cell viability. (a) Bar chart shows the proportion of LDH released as a proportion of total LDH following 
treatment of 3xTg-AD slice cultures with control (DMSO, 0 μM), 40 μM or 60 μM BTA-EG4 for 48 h. Data 
is mean ± SEM and is shown as fold change from control. n = 12. (b) Representative western blots of lysates 
prepared from 3xTg-AD slice cultures treated with 40–60 μM BTA-EG4 and control (DMSO, 0 μM) for 48 h 
probed with an antibody against N-terminal APP (22C11) and β-actin as a loading control. (b) Bar chart shows 
amounts of total APP relative to β-actin amounts in the same sample. n = 12. Data is mean ± SEM and is shown 
as fold change from control. (c) Amounts of Aβ-40 and Aβ-42 were measured in BTA-EG4-treated slice cultures 
using specific Aβ-40 and Aβ-42 ELISAs. Bar charts show amounts of Aβ-42 and Aβ-40. Data are shown in pg/
mL. The ratio of Aβ-42 relative to Aβ-40 is also shown. Data is mean ± SEM and are shown as fold control. 
n = 4. All data analysed by one-way ANOVA with post-hoc Dunnett’s multiple comparisons test.
www.nature.com/scientificreports/
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BTA-EG4 inhibits GSK-3 to reduce tau phosphorylation. BTA-EG4 has been previously reported 
to bind amyloid and increase Ras-mediated spinogenesis;9–11 however, its mechanisms of action are largely 
unknown. Since we have identified an effect of BTA-EG4 on tau phosphorylation, it was of interest to begin to 
examine the pathways by which this effect might occur. Increases in tau phosphorylation in AD are thought to 
be driven primarily by imbalances in kinases and phosphatases, including in two major tau kinases; GSK-3 and 
Cdk53, 36, 37. The site at which BTA-EG4 reduced tau phosphorylation in 3xTg-AD slice cultures (Ser202, recog-
nised by antibody CP13) is a known target of both GSK-3 and Cdk538, 39, therefore we investigated the effect of 
BTA-EG4 on the activities of these kinases.
GSK-3α/β is predominantly regulated by inhibitory phosphorylation of Ser21/9, which causes inactivation of 
GSK-3 and downstream reductions in tau phosphorylation24, 40, 41. Levels of total and inactive (phosphorylated 
Ser21/9) GSK-3 were determined by immunoblotting of BTA-EG4-treated 3xTg-AD slice cultures (Fig. 6a). Total 
amounts of GSK-3 were unaffected by treatment with BTA-EG4; however, phosphorylation of GSK-3 at Ser21/9 
was significantly increased by 60 μM, but not 40 μM, BTA-EG4, relative to controls (Fig. 6a, p < 0.05). These data 
suggest that BTA-EG4 inhibits GSK-3 activity in a dose-dependent manner that likely results in the reduced 
phosphorylation of tau at Ser202 observed with this treatment. In support of this finding, similar dose-dependent 
decreases in the phosphorylation of another GSK-3 substrate, β-catenin24, 42, were observed upon BTA-EG4 treat-
ment of slices in the absence of changes in total β-catenin amounts (Fig. 6b). To further investigate the mecha-
nism linking BTA-EG4 with GSK-3, western blots were probed with antibodies against Akt and p-Akt. Activation 
of the Akt/protein kinase B pathway by phosphorylation of Akt at sites including Ser473 allows increased inhibi-
tory phosphorylation of GSK-3α/β at Ser-924, 43. These data show a trend towards significantly increased phospho-
rylation of Akt at Ser473 relative to total Akt upon 60 μM but not 40 μM BTA-EG4 treatment (Fig. 6b) suggesting 
that BTA-EG4 likely inhibits GSK-3 activity in an Akt-dependent manner.
Figure 3. BTA-EG4 reduces tau phosphorylation in 3xTg-AD brain slice cultures. Representative western blots 
of lysates from 28 DIV BTA-EG4-treated and control (vehicle, DMSO)-treated 3xTg-AD slice cultures. Blots 
were probed with antibodies against total tau (both non-phosphorylated and phosphorylated; DAKO), PHF-1 
(phospho-Ser396/404), Tau-1 (dephospho-Ser199/202/Thr205) and CP13 (phospho-Ser202). Blots were also 
probed with an antibody against β-actin as a loading control. (C) Bar charts show amounts of total tau relative 
to β-actin in each sample, and phospho-tau as a proportion of total tau in each sample after treatment with 
BTA-EG4 or control. n = 12. Data is mean ± SEM and is shown as fold change from control. *p < 0.05. All data 
analysed by one-way ANOVA, with post-hoc Dunnett’s multiple comparisons test.
www.nature.com/scientificreports/
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Cdk5 activity is also known to drive phosphorylation of tau at Ser20239, 44. Cdk5 activity is predominantly reg-
ulated by its neuronal activators p35 and p2545–47, under physiological and pathological conditions, respectively48. 
Levels of total Cdk5 and amounts of p35 and p25 were analysed by immunoblotting (Fig. 6c) and were all found 
to be unaffected by BTA-EG4 (Fig. 6c), suggesting that the reductions in tau phosphorylation at Ser202 observed 
here are independent of Cdk5 and are likely to be mediated predominantly by inhibition of GSK-3 activity.
Discussion
We show here novel tau-directed effects of the amyloid-binding agent BTA-EG4 that are associated with its inhibi-
tion of GSK-3 activity. These data support the view that 3xTg-AD organotypic brain slice cultures provide a novel 
and reliable model for AD drug discovery.
We first validated 3xTg-AD slice cultures as a model for exploring drug effects by demonstrating that LiCl 
and NAP reduce tau phosphorylation and recapitulate the effects of their administration on tau in vivo17, 18. 
Importantly, the effects of these treatments were demonstrated here in 28 DIV cultures prepared from postnatal 
mouse pups, in contrast to prolonged treatment of adult 3xTg-AD mice. This highlights the notion that slice 
cultures can be used to provide an ex vivo model of the effects of AD-modifying treatments that is more time and 
cost-effective than currently used in vivo models, whilst significantly reducing the number of animals used and 
their aging to generate harmful phenotypes. Indeed, acute treatment of 3xTg-AD slice cultures with LiCl and 
NAP predicts changes in tau phosphorylation which have previously been confirmed with chronic treatment in 
vivo17, 18.
Based on these findings it is plausible that slice cultures can be screened for candidates which show efficacy 
over acute periods of time and these could then be extrapolated to a more chronic treatment in vivo.
We next explored the use of BTA-EG4 on AD-like molecular changes in these slice cultures. We have shown 
that treatment of 3xTg-AD slice cultures with BTA-EG4 reduces phosphorylation of tau at Ser202 in associa-
tion with GSK-3 inhibition that is mediated by increased GSK-3 phosphorylation at Ser21/9. Changes were also 
observed in Akt phosphorylation at Ser473, one of the sites implicated in Akt activation49, suggesting that the 
Figure 4. BTA-EG4 reduces tau phosphorylation and increases axonal tau distribution in 3xTg-AD brain slice 
cultures. Representative images from fixed 3xTg-AD organotypic brain slice cultures cultured for 28 DIV and 
treated with control (DMSO, 0 μM) or 60 μM BTA-EG4 for 48 h, immunolabelled with antibodies against total 
tau (both non-phosphorylated and phosphorylated; DAKO) - green and CP13 (phospho-Ser202) - red. Scale 
bar is 20 μm.
www.nature.com/scientificreports/
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effects on GSK-3 are mediated by Akt. Phosphorylation of tau at Ser202 is increased in AD brain50, and GSK-3 is 
a known kinase for this site44, 51. Tau is a major target for drug discovery in AD52 since tau accumulation is most 
closely associated with dementia in AD33, and tau is necessary for Aβ-induced neuronal loss13, 53 and deficits in 
long-term potentiation54. Therefore, this study supports further exploration of BTA-EG4 as a potential AD ther-
apeutic agent. We speculate based upon our findings in 3xTg-AD slice cultures that chronic BTA-EG4 treatment 
in vivo in these mice would also reduce tau phosphorylation mediated by GSK-3 inhibition, highlighting the 
predictive value slice culture systems can offer.
BTA-EG4 had previously been reported to have protective effects at the synapse in both WT and 3xTg-AD 
mice11, 12. In the slice culture system described here, no changes in levels of the pre-synaptic and post-synaptic 
markers, synaptophsyin and PSD-95, were observed upon treatment with BTA-EG4. This is likely due to the fact 
that 3xTg-AD slice cultures show no overt synapse loss at 28 DIV16. Alternatively, it has been suggested that slice 
cultures may develop stronger synaptic connectivity than in vivo and thus are less susceptible to synapse loss55.
BTA-EG4 increased the amount of sAPPα and reduced sAPPβ without affecting the total amount of APP 
in WT mice11, suggesting an ability of BTA-EG4 to alter APP processing. In agreement with this, we found no 
changes in the total amount of APP, and an apparent increase in mature APP. Due to the low levels of secreted 
sAPPα and sAPPβ, we were unable to measure these components in this study. In contrast to the findings of 
Megill et al.11 and Song et al.12; however, who treated WT and 3xTg-AD mice with BTA-EG4, respectively, we did 
not detect any changes in Aβ-40, nor did we observe any effects on Aβ-42 or the Aβ-42/Aβ-40 ratio. However, the 
reducing effect of BTA-EG4 treatment on Aβ-40 was lost in older 3xTg-AD mice12 and it is possible that the appar-
ent accelerated aging that occurs in 3xTg-AD slices16, may prevent any effect of BTA-EG4 effect on Aβ abundance 
in 3xTg-AD cultures. This finding further emphasises the critical importance of taking into account the disease 
stage when investigating potential AD-modifying treatments. It is also conceivable that in the 3xTg-AD slice 
Figure 5. Levels of synaptic markers and synaptic APP and tau are unaltered following BTA-EG4 treatment. 
Representative western blots of synaptosome fractions isolated following 48 h 40–60 μM BTA-EG4 and control 
(DMSO, 0 μM) treatment of 3xTg-AD slice cultures. Blots are probed with antibodies against (a) synaptophysin 
and PSD-95 and (b) N-terminal APP (22C11) and total tau (phosphorylated and non-phosphorylated; DAKO). 
Blots were also probed with an antibody against β-actin as a loading control. Bar charts show amounts of (a) 
PSD-95 or synaptophysin, and (b) N-terminal APP (22C11) or tau (DAKO) relative to β-actin levels in each 
sample. n = 5–10. Data is mean ± SEM shown as fold change from control. All data analysed by one-way 
ANOVA, with post-hoc Dunnett’s multiple comparisons test.
www.nature.com/scientificreports/
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cultures, BTA-EG4 is more potent towards reducing tau phosphorylation through GSK-3 inhibition compared 
to Aβ reduction likely by alternative mechanisms. With this in mind, we propose that BTA-EG4 is an effective 
GSK-3 inhibitor which potently reduces tau phosphorylation in a 3xTg-AD slice culture system. It is important to 
confirm these findings in vivo, but this adds to previous findings of others which show that BTA-EG4 is protective 
against Aβ and is synaptotrophic in vivo11, 12 highlighting the potential of BTA-EG4 to target three major features 
of AD.
To conclude, we have highlighted the utility of 3xTg-AD brain slice cultures for AD drug discovery and devel-
opment. We show the value of this system for identifying molecular changes relevant for investigating new AD 
treatments in a significantly shorter timescale than exists in in vivo paradigms. We have also identified novel 
tau-directed effects of BTA-EG4 that are associated with inhibition of GSK-3. Taken together, these findings sup-
port further investigation into the potential beneficial effects of BTA-EG4 and similar compounds for AD and 
related tauopathies.
Methods and Materials
All materials were obtained from Sigma (Poole, Dorset, UK) unless otherwise stated.
Mice and preparation of organotypic brain slice cultures. 3xTg-AD20, 21 mice were used in this study. 
All methods were carried out in accordance with the UK Animals (Scientific Procedures) Act 1986. All experi-
ments with mice were conducted under UK Home Office Personal and Project Licenses and with agreement from 
the King’s College London (Denmark Hill) Animal Welfare and Ethical Review Board.
Figure 6. BTA-EG4 inhibits GSK-3 but not Cdk5 in 3xTg-AD slice cultures. Representative western blots of 
lysates following 48 h 40–60 μM BTA-EG4 and control (DMSO, 0 μM) treatment of 3xTg-AD slice cultures. (a) 
Blots were probed with antibodies against total GSK-3α/β and inactive GSK-3α/β (phosphorylated at ser 21/9). 
Bar chart shows amounts of total GSK-3 relative to β-actin and GSK-3 phosphorylated at ser 21/9 (inactive) as 
a proportion of total GSK-3, n = 12. (b) Western blots of β-catenin and β-catenin phosphorylated at ser 552, 
total Akt and active Akt (phosphorylated at ser 473), together with β-actin as a loading control. Bar charts show 
p-β-catenin relative to total β-catenin and β-catenin following normalisation to β-actin, and p-Akt relative to 
Akt and total Akt following normalisation to β-actin, n = 3. (c) Samples were immunoblotted with antibodies 
against cdk5, p35 (which also detects p25) β-actin. Bar charts show total Cdk5 relative to β-actin and p35/p25 
as a proportion of Cdk5 in each sample. n = 12. All data is mean ± SEM and are shown as fold change from 
control. *p < 0.05. All data analysed by one-way ANOVA, with post-hoc Dunnett’s multiple comparisons test.
www.nature.com/scientificreports/
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Slice cultures were prepared from postnatal day 8–9 3xTg-AD20, 21 mice, as previously described16. In brief, 
pups were decapitated and the brains removed and dissected to retain the cortex, hippocampus and connecting 
regions in each hemi-brain in sterile filtered ice-cold dissection buffer (1.25 mM KH2PO4, 124 mM NaCl (pH 7.4), 
3 mM KCl, 8.19 mM MgSO4, 2.65 mM CaCl2, 3.5 mM NaHCO3, 10 mM glucose, 2 mM ascorbic acid, 39.4 μM 
ATP in ultrapure H2O). The hemi-brain was placed on filter paper and 350 µm coronal slices were cut using a 
McIllwainTM tissue chopper (Mickle Laboratory Engineering Co. Ltd., Surrey, UK). The 18, 350 μM slices were 
collected and plated in sequence; three consecutive slices per semi-porous membrane insert (Millipore, 0.4 µm 
pore diameter, Fisher Scientific, Loughborough, UK) in 6-well sterile culture plates. Slices from the same part of 
the brain are therefore in the same wells of each plate. For treatments; the same wells in each plate were treated 
with vehicle or drug allowing comparison of drug effects in the same brain areas. Slices were maintained at 37 °C 
and 5% CO2 in sterile-filtered culture medium containing basal medium eagle (BME), 26.6 mM HEPES (pH 7.1), 
19.3 mM NaCl, 5 mM NaHCO3, 511 μM ascorbic acid, 40 mM glucose, 2.7 mM CaCl2, 2.5 mM MgSO4, 1% (v/v) 
GlutaMAX (Life Technologies, Paisley, UK), 0.033% (v/v) insulin, 50 U/ml penicillin, 50 μg/ml streptomycin and 
25% (v/v) heat-inactivated horse serum. Culture medium was changed every 2–3 days. Slice cultures were treated 
after 28 days in vitro with 40–60 μM BTA-EG4 for 48 h, 20 mM LiCl for 4 h, 100 nM NAP (Alpha Diagnostic 
International, TX, USA) for 24 h, and with the appropriate vehicles.
Cytotoxicity assays. Cell death in slice cultures was evaluated by measuring LDH in culture medium using 
Cytotox 96 assay kits (Promega, Madison, WI, USA), according to the manufacturer’s protocol. Optical density 
was measured at 492 nm (Wallac 1420 Victor3 plate reader, PerkinElmer, Waltham, MA, USA). LDH content in 
medium and lysed slice cultures was summed to determine total LDH content. LDH release from slice cultures 
was calculated as a percentage of total LDH (LDH in medium and LDH in slice cultures) in each sample.
Preparation of slice culture lysates for western blotting. After treatments, medium was removed 
and slice cultures were washed in ice-cold phosphate-buffered saline (PBS), followed by lysis in extra strong lysis 
buffer (10 mM Tris-HCl (pH 7.5), 0.5% (w/v) sodium dodecyl sulphate (SDS), 20 mM sodium deoxycholate, 
1% (v/v) Triton-X-100, 75 mM sodium chloride, 10 mM ethylenediaminetetraacetic acid (EDTA), 2 mM sodium 
orthovanadate, 1.25 mM sodium fluoride, and Complete protease inhibitor cocktail (Roche Diagnostics, UK)), 
and centrifugation at 16,000 gav for 20 min at 4 °C. The protein concentration of supernatants was measured using 
a BCA protein assay kit (Pierce Endogen, Rockford, USA) and samples were standardised to equal protein con-
centration before being analysed by SDS-PAGE.
Preparation of synaptosomes. Synaptosomes were prepared as previously described16, 56. In brief, slices 
were homogenised in synaptosome lysis buffer (10 mM Tris HCl, pH 7.4, containing 0.32 M sucrose, 2 mM 
EGTA, 2 mM EDTA and Complete protease inhibitor cocktail [Roche, Mannheim, Germany]) and centrifuged at 
1,000 g(av) for 10 minutes at 4 °C to remove cell nuclei and debris. The supernatant (“total fraction”) was then cen-
trifuged at 10,000 g(av) for 20 minutes at 4 °C. The final pellet (“synaptosomes”) was resuspended in 2x Laemmli 
buffer before immunoblotting for pre- and post-synaptic markers.
Aβ ELISA. Quantification of Aβ1-40 and Aβ1-42 in slice lysates was performed using ELISA kits from 
Invitrogen (Aβ1-40 ELISA KHB3481; Aβ1-42 ELISA KHB3442) as we have previously described36. Aβ1-40 and 
Aβ1-42 standards of known concentration were plated to generate a standard curve from which Aβ content was 
measured. Absorbance was read at 450 nm.
SDS-PAGE and Immunoblotting. 5–20 µg protein was separated on 10% (w/v) SDS-PAGE gels and elec-
trophoretically transferred to nitrocellulose membrane. After blocking with 5% (w/v) non-fat dried milk for 
1 hour, membranes were probed with primary antibodies, followed by fluorophore-coupled secondary antibodies. 
Detected proteins were visualised and quantified using an Odyssey infrared imaging and analysis system (Li-Cor 
Biosciences, Cambridge, UK). This method enables sensitive and robust detection of protein amounts across 
a wide quantitative linear range57, in contrast to semi-quantitative chemiluminescence methods. Importantly, 
saturated signals are indicated when scanning and these cannot be quantified. The following primary antibod-
ies were used for western blotting; total tau (rabbit IgG; Dako Ltd., Ely, UK); APP (mouse IgG1, clone 22c11; 
Millipore UK Ltd; Watford, UK), total GSK-3α/β (Mouse IgG2b, Clone 1H8, Enzo Life Sciences, Exeter, UK), 
GSK-3α/β-pSer21/9 (rabbit IgG, New England Biolabs, Hitchin, UK), pan-Akt (mouse IgG, Cell Signaling, 
Beverly, MA), Akt-pSer473 (rabbit IgG, Cell Signaling, Beverly, MA), β-catenin (mouse IgG, Abcam, Cambridge, 
UK), β-catenin-pSer552 (Sigma, Poole, Dorset, UK), Cdk5 (mouse IgG1, clone J-3; Santa Cruz Biotechnology, 
Santa Cruz, USA), p35 (rabbit IgG, clone C-19, Santa Cruz Biotechnology, Santa Cruz, USA), synaptophysin 
(mouse IgM, clone SP15; Enzo Life Sciences, Exeter, UK), PSD-95 (rabbit IgG, Cell Signaling, USA), β-actin 
(mouse IgG1, clone AC-15, Abcam, Cambridge, UK). The following tau antibodies were kindly gifted by Peter 
Davies (Albert Einstein College of Medicine, Bronx, NY, USA): CP13 (phospho-Ser-202; mouse IgG1), PHF-1 
(phospho-Ser-396/404; mouse IgG1), Tg3 (phospho-Thr-231; mouse IgM)58, 59.
Immunofluorescent staining. Organotypic brain slice cultures were fixed on their membrane inserts in 
4% PFA for 4 h and stained according to Gogolla et al.60. In brief, slice cultures were cut out whilst still on their 
membranes and then treated as free-floating sections. Slice cultures were permeabilised for 18 h in 0.5% Triton 
X-100 at 4 °C and then blocked in 20% bovine serum albumin (BSA) for 4 h at room temperature (RT). Slice cul-
tures were incubated in total tau and CP13 (as above) primary antibodies overnight at 4 °C in 5% BSA, washed 
and then incubated in fluorophore-coupled secondary antibodies for 4 h at RT. Slice cultures were washed a final 
time before mounting on slides with fluorescent mounting medium (Dako Ltd., Ely, UK). Slice cultures were 
imaged using an Eclipse Ti-E Inverted (Nikon Instruments, UK) microscope using a CSU-X1 Spinning Disk 
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Confocal and Andor Ixon3 EM-CCD camera imaging system setup using a 60 Plan Apo VC N2 objective lens 
(Nikon Instruments, UK).
Statistics. Data were analysed using either Student’s unpaired t-test or one-way analysis of variance 
(Graphpad Prism 6.0 Software), followed by Dunnett’s post-hoc tests when data was determined to follow the 
normal distribution according to the Shapiro-Wilk test. If data were not normally distributed, non-parametric 
tests (Mann Whitney U test, Kruskal-Wallis test) were performed. Differences were considered statistically sig-
nificant when p < 0.05. For all slice culture experiments, N refers to the number of wells, each of which contain 
three brain slices. For N = 9, this is based on 3 wells from 3 independent experiments.
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